<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854383</url>
  </required_header>
  <id_info>
    <org_study_id>600181</org_study_id>
    <nct_id>NCT03854383</nct_id>
  </id_info>
  <brief_title>Using Isosorbide Mononitrate in Reducing Time in Induction of Labor in Post Date Women</brief_title>
  <official_title>Efficacy of Intravaginal Administration of Isosorbide Mononitrate Together With Misoprostol Versus Misoprostol Alone in Induction of Labor in Postdate Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdelrahman Ali Fadel Youssef Mohamed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will compare between using isosorbide mononitrate together with misoprostol versus the
      misoprostol alone in induction of labor in postdate women
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of induction to active phase interval</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure the time between the beginning of the induction to enter the active phase of labor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>Misoprostol alone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide mononitrate with misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide mononitrate</intervention_name>
    <description>Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women</description>
    <arm_group_label>Isosorbide mononitrate with misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Used intravaginally to ripe the cevix in induction of labor</description>
    <arm_group_label>Isosorbide mononitrate with misoprostol</arm_group_label>
    <arm_group_label>Misoprostol alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age (20-35 yrs)

          -  single fetus

          -  gestational age &gt; 40weeks

          -  not in labor

          -  bishop score &lt; 7

          -  no medical disorder

        Exclusion Criteria:

          -  Gestational age ≤40 weeks

          -  patient with a ripe cervix

          -  rupture of membranes

          -  suspected chorioamnionitis

          -  placenta previa

          -  history of major uterine surgery

          -  hypertonic uterine pattern

          -  contraindicated to receive PG

          -  fetal malpresentation

          -  multiple pregnancy

          -  intrauterine growth retardation

          -  women with any general medical disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams maternity hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11517</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saed Mousa, PhD</last_name>
      <phone>1008687700</phone>
      <phone_ext>+20</phone_ext>
      <email>drsaedmousa1@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>March 9, 2019</last_update_submitted>
  <last_update_submitted_qc>March 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Abdelrahman Ali Fadel Youssef Mohamed</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 25, 2019</submitted>
    <returned>September 5, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

